Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Finished Goods: 2014-2018

Historic Finished Goods for Vanda Pharmaceuticals (VNDA) over the last 3 years, with Mar 2018 value amounting to $1.0 million.

  • Vanda Pharmaceuticals' Finished Goods rose 31.98% to $1.0 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.0 million, marking a year-over-year increase of 31.98%. This contributed to the annual value of $760,000 for FY2017, which is 0.26% down from last year.
  • Vanda Pharmaceuticals' Finished Goods amounted to $1.0 million in Q1 2018, which was up 33.03% from $760,000 recorded in Q4 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' Finished Goods peaked at $3.4 million during Q4 2014, and registered a low of $611,000 during Q2 2017.
  • Over the past 3 years, Vanda Pharmaceuticals' median Finished Goods value was $764,000 (recorded in 2016), while the average stood at $794,667.
  • Examining YoY changes over the last 5 years, Vanda Pharmaceuticals' Finished Goods showed a top increase of 181.19% in 2015 and a maximum decrease of 61.87% in 2015.
  • Over the past 5 years, Vanda Pharmaceuticals' Finished Goods (Quarterly) stood at $3.4 million in 2014, then crashed by 61.87% to $1.3 million in 2015, then tumbled by 41.11% to $762,000 in 2016, then dropped by 0.26% to $760,000 in 2017, then surged by 31.98% to $1.0 million in 2018.
  • Its Finished Goods was $1.0 million in Q1 2018, compared to $760,000 in Q4 2017 and $858,000 in Q3 2017.